이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

CSPC Pharmaceutical Group 관리

관리 기준 확인 2/4

CSPC Pharmaceutical Group's CEO는 Cuilong Zhang, May2022 에 임명되었습니다 의 임기는 2.08 년입니다. 총 연간 보상은 CN¥ 13.47M, 5.1% 로 구성됩니다. 5.1% 급여 및 94.9% 보너스(회사 주식 및 옵션 포함). 는 HK$ 26.92M 가치에 해당하는 회사 주식의 0.034% 직접 소유합니다. 26.92M. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 7.3 년입니다.

주요 정보

Cuilong Zhang

최고 경영자

CN¥13.5m

총 보상

CEO 급여 비율	5.1%
CEO 임기	2.3yrs
CEO 소유권	0.04%
경영진 평균 재임 기간	2.9yrs
이사회 평균 재임 기간	7.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Cuilong Zhang 의 보수는 CSPC Pharmaceutical Group 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	CN¥6b
Mar 31 2024	n/a	n/a	CN¥6b
Dec 31 2023	CN¥13m	CN¥693k	CN¥6b
Sep 30 2023	n/a	n/a	CN¥6b
Jun 30 2023	n/a	n/a	CN¥6b
Mar 31 2023	n/a	n/a	CN¥6b
Dec 31 2022	CN¥11m	CN¥693k	CN¥6b
Sep 30 2022	n/a	n/a	CN¥6b
Jun 30 2022	n/a	n/a	CN¥6b
Mar 31 2022	n/a	n/a	CN¥6b
Dec 31 2021	CN¥9m	CN¥693k	CN¥6b
Sep 30 2021	n/a	n/a	CN¥6b
Jun 30 2021	n/a	n/a	CN¥6b
Mar 31 2021	n/a	n/a	CN¥5b
Dec 31 2020	CN¥9m	CN¥693k	CN¥5b
Sep 30 2020	n/a	n/a	CN¥4b
Jun 30 2020	n/a	n/a	CN¥4b
Mar 31 2020	n/a	n/a	CN¥4b
Dec 31 2019	CN¥7m	CN¥693k	CN¥4b
Sep 30 2019	n/a	n/a	CN¥4b
Jun 30 2019	n/a	n/a	CN¥3b
Mar 31 2019	n/a	n/a	CN¥3b
Dec 31 2018	CN¥4m	CN¥298k	CN¥3b

보상 대 시장: Cuilong 의 총 보상 ($USD 1.86M )은 Hong Kong 시장( $USD 891.29K ).

보상과 수익: Cuilong 의 보상은 작년에 20% 이상 증가한 반면 회사 수익은 20% 이상 감소했습니다.

CEO

Cuilong Zhang (55 yo)

2.3yrs

테뉴어

CN¥13,472,000

보상

Mr. Cuilong Zhang has been the Vice Chairman of CSPC Pharmaceutical Group Ltd since May 21, 2019 and serves as its Chief Executive Officer since May 27, 2022. He was Rotating Chief Executive Officer of CSP...

리더십 팀

이름	위치	테뉴어	보상	소유권
Dongchen Cai	Executive Chairman	27.3yrs	CN¥26.68m	23.93% CN¥ 13.6b
Cuilong Zhang	Vice-Chairman & CEO	2.3yrs	CN¥13.47m	0.043% CN¥ 24.1m
Chunlei Li	Executive Director & Chief Scientist	6.7yrs	CN¥9.42m	0.038% CN¥ 21.7m
Weidong Pan	Executive Director	no data	CN¥4.92m	0.013% CN¥ 7.2m
Huaiyu Wang	Executive Director	no data	CN¥5.74m	0.013% CN¥ 7.2m
Zhenguo Wang	Executive Director	no data	CN¥4.90m	0.013% CN¥ 7.2m
Hao Jiang	Executive Director	no data	CN¥4.02m	0.025% CN¥ 14.4m
Xin Cai	Group Executive President	no data	데이터 없음	데이터 없음
Bing Yao	Executive Director	less than a year	데이터 없음	데이터 없음
Tai On Lo	Company Secretary	3.6yrs	데이터 없음	데이터 없음

2.9yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: 1093 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Dongchen Cai	Executive Chairman	27.3yrs	CN¥26.68m	23.93% CN¥ 13.6b
Cuilong Zhang	Vice-Chairman & CEO	6.1yrs	CN¥13.47m	0.043% CN¥ 24.1m
Chunlei Li	Executive Director & Chief Scientist	6.7yrs	CN¥9.42m	0.038% CN¥ 21.7m
Weidong Pan	Executive Director	17.8yrs	CN¥4.92m	0.013% CN¥ 7.2m
Huaiyu Wang	Executive Director	13.8yrs	CN¥5.74m	0.013% CN¥ 7.2m
Zhenguo Wang	Executive Director	12.6yrs	CN¥4.90m	0.013% CN¥ 7.2m
Hao Jiang	Executive Director	3.8yrs	CN¥4.02m	0.025% CN¥ 14.4m
Xin Cai	Group Executive President	less than a year	데이터 없음	데이터 없음
Bing Yao	Executive Director	less than a year	데이터 없음	데이터 없음
Chun Kwok Au	Independent Non-Executive Director	3.6yrs	CN¥340.00k	데이터 없음
Bo Wang	Independent Non-Executive Director	11.7yrs	CN¥142.00k	데이터 없음
Chuan Chen	Independent Non-Executive Director	8.2yrs	CN¥142.00k	데이터 없음

7.4yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 이사회: 1093 의 이사회는 경험(평균 재직 기간 7.3 년)으로 간주됩니다.

CSPC Pharmaceutical Group 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Executive Chairman recently bought HK$6.7m worth of stock

CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024

Executive Chairman recently bought HK$13m worth of stock

CSPC Pharmaceutical Group Limited Appoints Li Quan as an Independent Non-Executive Director

CSPC Pharmaceutical Group Announces Resignation of Wu Guizhen as Independent Non-Executive Director

CSPC Pharmaceutical Group Limited Announces Change of CEO

Recent updates

Investor sentiment deteriorates as stock falls 17%

Executive Chairman recently bought HK$6.7m worth of stock

Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023)

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024

CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces Enlonstobart Injection Obtains Conditional Marketing Approval

CSPC Pharmaceutical Group Limited Obtains Approval from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023

First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 1Q 2023)

Upcoming dividend of HK$0.14 per share

CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug (JMT202) Obtains Approval from National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited to Report Q1, 2024 Results on May 27, 2024

CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023

Full year 2023 earnings released: EPS: CN¥0.49 (vs CN¥0.51 in FY 2022)

CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S

CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval

CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings released: EPS: CN¥0.49 (vs CN¥0.51 in FY 2022)

CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate SYS6023 Obtains Clinical Trial Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024

CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration

CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA

CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets

CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.13 in 3Q 2022)

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023

CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE

CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval

Investor sentiment improves as stock rises 19%

CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors

CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA

Upcoming dividend of HK$0.14 per share at 4.7% yield

CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.13 in 2Q 2022)

CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023

Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161)

CSPC Ouyi Pharmaceutical Co., Ltd. Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

Cspc Pharmaceutical Group Limited Announces That Clinical Trial Application for Cpo301

Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China

Elevation Oncology Highlights First-In-Human Phase 1 Sysa1801 (Eo-3021) Clinical Data to Be Presented by Partner Cspc Pharmaceutical Group Limited At Asco 2023

CSPC Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.11 per share at 3.1% yield

First quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 1Q 2022)

CSPC Pharmaceutical Group Limited to Report Q1, 2023 Results on May 25, 2023

Executive Chairman recently bought HK$13m worth of stock

Full year 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.47 in FY 2021)

CSPC Pharmaceutical Group Limited Announces Highly Selective PRMT5 Inhibitor SYH2045 Obtains Clinical Trial Approval

Cspc Pharmaceutical Group Limited Announces ALMB-0166 for the Treatment of Osteoarthritis Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Receives Approval for SYH2043 from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces NBL-020 for the Treatment of Advanced Solid Tumors Obtains Clinical Trial Approval in the U.S

Cspc Pharmaceutical Group Limited Announces That Syh2055 Developed by the Group Has Obtained Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate CPO204 Obtains Clinical Trial Approval in the U.S

Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 3Q 2021)

CSPC Pharmaceutical Group Limited's SYHX1901 Tablets Obtains Approval Granted by the National Medical Products Administration

CSPC Pharmaceutical Group Limited Announces New Indication Application for Marketing Approval of Mingfule

CSPC Pharmaceutical Group Limited to Report Nine Months, 2022 Results on Nov 23, 2022

CSPC Pharmaceutical Group Limited Appoints Li Quan as an Independent Non-Executive Director

Investor sentiment improved over the past week

CSPC Pharmaceutical Group Limited Announces the Antibody-Drug Conjugate Sys6002

CSPC Pharmaceutical Group Limited Announces TG103 Injection Obtains Clinical Trial Approval for the Treatment of Non-Alcoholic Steatohepatitis